We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
Read MoreHide Full Article
Revvity, Inc. (RVTY - Free Report) announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. Per management, it is currently the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma.
The results on EUROIMMUN’s ChLIA platforms are expected to be rapidly available, with the first result available under an hour (in 48 minutes). It also has an estimated throughput of nearly 60 tests per hour.
The latest regulatory clearance is a significant stepping stone for Revvity to advance its diagnostic capabilities for androgen disorders.
Likely Trend of RVTY Stock Following the News
Following the announcement, shares of the company lost nearly 2.2% till Friday’s closing.
Historically, the company has gained a top-line boost from its various regulatory achievements and product launches. Although the latest FDA approval is likely to be beneficial for RVTY’s top-line growth going forward, the stock declined overall.
Revvity currently has a market capitalization of $13.86 billion. It has an earnings yield of 4.4%, favorable than the industry’s 3.7%. In the last reported quarter, RVTY delivered an earnings surprise of 13.3%.
Significance of the FDA Approval for Revvity
Per Revvity, the assay is processed on the company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing. It needs minimal technician training and expertise to handle while maintaining high accuracy and reliability. The assay is expected to provide direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism and impotence, among others.
Management believes that the regulatory clearance will likely expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions with assays that serves a diverse patient pool across all demographics.
Industry Prospects in Favor of RVTY
Per a report by Future Market Insights, the global testosterone test market recorded a market valuation of $100 million in 2023 and is anticipated to reach $208.1 million by 2034 at a CAGR of 6.9%. Factors like the rising awareness about hormonal disorders and the increasing prevalence of male infertility are likely to drive the market.
Given the market potential, the latest FDA clearance is expected to be a significant milestone for Revvity and boost its business.
Revvity’s Notable Developments
In November 2024, Revvity announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.
The same month, Revvity announced its third-quarter 2024 results, wherein it reported a solid growth in its revenues both on a reported and organic basis.
RVTY’s Share Price Performance
Shares of the company have gained 2.8% in the past year against the industry’s 9.8% decline. The S&P 500 has gained 23% in the same time frame.
Image Source: Zacks Investment Research
Revvity’s Zacks Rank & Key Picks
Currently, RVTY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , ResMed Inc. (RMD - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.5%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health’s shares have gained 14.9% compared with the industry’s 2.1% growth in the past year.
ResMed, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.
ResMed has gained 34.5% compared with the industry’s 7.8% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.3%.
Boston Scientific’s shares have rallied 58.3% compared with the industry’s 7.8% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
Revvity, Inc. (RVTY - Free Report) announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. Per management, it is currently the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma.
The results on EUROIMMUN’s ChLIA platforms are expected to be rapidly available, with the first result available under an hour (in 48 minutes). It also has an estimated throughput of nearly 60 tests per hour.
The latest regulatory clearance is a significant stepping stone for Revvity to advance its diagnostic capabilities for androgen disorders.
Likely Trend of RVTY Stock Following the News
Following the announcement, shares of the company lost nearly 2.2% till Friday’s closing.
Historically, the company has gained a top-line boost from its various regulatory achievements and product launches. Although the latest FDA approval is likely to be beneficial for RVTY’s top-line growth going forward, the stock declined overall.
Revvity currently has a market capitalization of $13.86 billion. It has an earnings yield of 4.4%, favorable than the industry’s 3.7%. In the last reported quarter, RVTY delivered an earnings surprise of 13.3%.
Significance of the FDA Approval for Revvity
Per Revvity, the assay is processed on the company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing. It needs minimal technician training and expertise to handle while maintaining high accuracy and reliability. The assay is expected to provide direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism and impotence, among others.
Management believes that the regulatory clearance will likely expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions with assays that serves a diverse patient pool across all demographics.
Industry Prospects in Favor of RVTY
Per a report by Future Market Insights, the global testosterone test market recorded a market valuation of $100 million in 2023 and is anticipated to reach $208.1 million by 2034 at a CAGR of 6.9%. Factors like the rising awareness about hormonal disorders and the increasing prevalence of male infertility are likely to drive the market.
Given the market potential, the latest FDA clearance is expected to be a significant milestone for Revvity and boost its business.
Revvity’s Notable Developments
In November 2024, Revvity announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom.
The same month, Revvity announced its third-quarter 2024 results, wherein it reported a solid growth in its revenues both on a reported and organic basis.
RVTY’s Share Price Performance
Shares of the company have gained 2.8% in the past year against the industry’s 9.8% decline. The S&P 500 has gained 23% in the same time frame.
Image Source: Zacks Investment Research
Revvity’s Zacks Rank & Key Picks
Currently, RVTY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , ResMed Inc. (RMD - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.5%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health’s shares have gained 14.9% compared with the industry’s 2.1% growth in the past year.
ResMed, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.
ResMed has gained 34.5% compared with the industry’s 7.8% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.3%.
Boston Scientific’s shares have rallied 58.3% compared with the industry’s 7.8% growth in the past year.